Yidu Tech Inc. Announces Successful Bid for Phase III Clinical Study of SMR001 Eye Drops
Yidu Tech Inc. has announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured the bid for a Phase III Clinical Study Project involving the Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The project, commissioned by Shandong Yandu Biotechnology Co., Ltd., has a total value of approximately RMB55,817,597.00. The clinical study aims to further investigate the efficacy and safety of the eye drop. The results of this study have not yet been presented and will be shared in the future. Yidu Tech continues to leverage its AI-powered technologies to enhance healthcare delivery and accelerate pharmaceutical development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。